KPV

What it is (in plain language)
- It is a natural 'fire extinguisher' for inflammation. KPV acts inside cells to deactivate inflammatory pathways (such as NF-kB). It is particularly effective on the skin and digestive tract, helping to calm conditions such as colitis or dermatitis without the side effects of corticosteroids.

Why do you appear online so much
- It has gained fame in the treatment of autoimmune diseases, mast cell activation syndrome (MCAS) and chronic intestinal problems. As it is a very small peptide, it can be absorbed in various ways, including orally or in creams.

How it is framed today (pragmatic view)
- 1) Evidence: Solid in dermatology and experimental gastroenterology. 2) Objective: Reduction of chronic inflammation and repair of the intestinal barrier. 3) Risk: Very high safety profile, being one of the most natural and least invasive peptides.

How to use this form
- Explore the 'Handling Notes' section to learn about the stability of this peptide in different delivery vehicles.

- Quick profile (curated by Subject 157)
- Class: Other
- Status: Verified
- Use case: Other
- Route: Oral
- Tags: Oral|Injectable|Gut|Anti-Inflammatory
- Half-life: Unknown
- Start: Variable
- Duration: Variable

- Mechanism (high level)
C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH. Inhibits NF-kB translocation, reducing inflammation. Has direct antimicrobial activity against C. albicans.

- Evidence (what the literature covers)
RESEARCH RANGE (Non-prescriptive):
Oral doses of 200mcg to 500mcg.
Level of Evidence: C (Pre-clinical).

- Safety and harm-reduction (non-prescriptive)
Risks: No serious adverse effects reported.
Interactions: Unknown.

- References (anchors)
- Dalmasso, G. (2008) - KPV peptide in experimental colitis / anti-inflammatory response - https://doi.org/10.1002/ibd.20334
- PubMed:18092346

Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.